CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer

PURPOSE: Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and adjuvant chemotherapy have an expected survival of only two years due to disease recurrence, frequently in the liver. We investigated the role of liver macrophages in progression of PDAC micrometastases...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Michaels, Alex D., Newhook, Timothy E., Adair, Sara J., Morioka, Sho, Goudreau, Bernadette J., Nagdas, Sarbajeet, Mullen, Matthew G., Persily, Jesse B., Bullock, Timothy N. J., Slingluff, Craig L., Ravichandran, Kodi S., Thomas Parsons, J., Bauer, Todd W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6296745/
https://ncbi.nlm.nih.gov/pubmed/29288236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2283
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados